Johnson & Johnson said its combination therapy for lung cancer outperformed AstraZeneca Plc’s blockbuster Tagrisso in a ...
Michael Truskoski learned he has stage 4 lung cancer after he had a seizure at work just over three weeks ago, the result of cancer that spread to his brain.
Johnson & Johnson said a combination of its lung cancer drugs Rybrevant and Lazcluze kept people alive for at least a year longer than AstraZeneca's Tagrisso in a clinical trial. J&J is trying to ...
Luis E. Raez, MD, discusses when minimal residual disease testing can be performed as an option for patients with lung cancer.
Gastric cancer, commonly known as stomach cancer, is the fifth most common cancer globally and the fifth leading cause of ...
Here are some of the drugs that are predicted to become blockbusters in the next few years, according to Clarivate's latest ...
HIFU technology addressing pancreatic tumors has been developed in cooperation with LabTAU ( Laboratory of Therapeutic Applications of Ultrasound) a joint research unit under the academic authorities ...
More than 66,000 Americans will be diagnosed with pancreatic cancer this year. Learn more about the disease and how PanCAN can help.